Quest Diagnostics Inc Net Fee Amt
Quest Diagnostics Inc (DGX) had Net Fee Amt of $68.19 thousand as of 2026-04-27, per its 424B2 filed 2026-04-28.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-28
- 2026-04-27: Net Fee Amt $68.19K.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-27 | $68.19K 424B2 · filed 2026-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |